(Q35688896)

9 August 2017

title

Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

6

Raymond T Chung

1 reference

9 August 2017

Andrew S Ross

1

1 reference

9 August 2017

Atul K Bhan

2

1 reference

9 August 2017

Manuel Pascual

3

1 reference

9 August 2017

Michael Thiim

4

1 reference

9 August 2017

A Benedict Cosimi

5

1 reference

9 August 2017

publication date

1 April 2004

1 reference

9 August 2017

published in

Clinical Transplantation

1 reference

9 August 2017

volume

18

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

166-173

1 reference

Hepatitis C after liver transplantation.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Management of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-0012.2003.00145.X

10.1046/J.1399-0012.2003.00145.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference